Family History, and Impact on Clinical Presentation and Prognosis, in a Population-based Breast Cancer Cohort from the Stockholm County
The aim of the present study was to define the proportion of different levels of family history in a cohort of consecutive breast cancer patients from the Stockholm region, and to assess whether familial breast cancer has phenotypic traits different from those of sporadic patients.
All incident breast cancer patients in a 19-month period were eligible for the study and 70% (489/696) participated. The family history and clinical parameters were obtained from questionnaires and medical records.
In total 35% had a family history. Age at onset was 58.9 years in the familial group vs. 60.7 years in the sporadic patients (P = 0.14) and 8% of the familial patients had bilateral breast cancer compared to 4% in the sporadic group (P = 0.08). There were 31% node positive tumors in the sporadic group vs. 22% in the cases with family history (P = 0.04). Hormonal background, treatment and prognosis (median follow-up 4.7 years) were not related to family history.
In addition to high-risk familial breast and breast-ovarian cancer, constituting about 10% of all breast cancer cases, another 25% of the breast cancer cases have a family history, a group hypothetically valuable for association studies on low-risk genes. In contrast to previous reports, we did not observe a relationship between family history and phenotypic traits. A possible explanation for this can be different study design. The considerable heterogeneity in familial breast cancer means that different criteria for familiality can influence the result. Furthermore, our study was prospective and population based and included paternal inheritance.
KeywordsPopulation based Breast cancer Family history Prognosis
hazard rate ratio
patients with family history
no statistically significant difference
breast cancer gene
hormone replacement therapy
Unable to display preview. Download preview PDF.
- 1.Socialstyrelsen (2002) Epidemiologiskt centrum., Medicinalstyrelsen. and Socialstyrelsen. Cancerregistret. Cancer incidence in Sweden. Socialstyrelsen, Statistik. Hälsa och sjukdomar, StockholmGoogle Scholar
- 5.Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689PubMedCrossRefGoogle Scholar
- 22.Wobbes T, van de Wiel MP, van der Sluis RF, Theeuwes AG (1987) The effect of familiality on clinical presentation and survival in mammary carcinoma. Eur J Surg Oncol l13:119–121Google Scholar
- 28.Pathology of familial breast cancer (1997) differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 349:1505–1510Google Scholar
- 31.Kinoshita T, Fukutomi T, Iwamoto E, Akashi-Tanaka S (2004) Prognosis of breast cancer patients with familial history classified according to their menopausal status. Br J Cancer 10:218–222Google Scholar
- 40.Zelada-Hedman M, Wasteson Arver B, Claro A, Chen J, Werelius B, Kok H, Sandelin K, Hakansson S, Andersen TI, Borg A, Borresen Dale AL, Lindblom A (1997) A screening for BRCA1 mutations in breast and breast–ovarian cancer families from the Stockholm region. Cancer Res 57:2474–2477PubMedGoogle Scholar
- 50.Vårdprogram Ba, Onkologiskt Centrum Stockholm-GotlandGoogle Scholar